Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.
Monday, November 2, 2009
New TAU Formulation May Slow Down Parkinson's, Alzheimer's And Huntington's Diseases
Posted by Heather Dugdale at 11:50 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment